Skip to main content

CD19 / CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19 / CD22-expressing B Cell Malignancies

Trial Status: Active

Background: B-cell leukemias and lymphomas are cancers that are often difficult to treat. The primary objective of this study is to determine the ability to take a patient's own cells (T lymphocytes) and grow them in the laboratory with the CD19 / CD22-CAR receptor gene through a process called 'lentiviral transduction (also considered gene therapy) and growing them to large numbers to use as a treatment for hematologic cancers in children and young adults.. Researchers want to see if giving modified CD19 / CD22-CAR T cells to people with these cancers can attack cancer cells. In addition, the safety of giving these gene modified cells to humans will be tested at different cell doses. Additional objectives are to determine if this therapy can cause regression of B cell cancers and to measure if the gene modified cells survive in patients blood. Objective: To study the safety and effects of giving CD19 / CD22-CAR T cells to children and young adults with B-cell cancer. Eligibility: People ages 3 35 with certain cancers that have not been cured by standard therapy. Their cancer tissue must express the CD19 protein. Design: A sample of participants blood or bone marrow will be sent to NIH and tested for leukemia. Participants will be screened with: Medical history Physical exam Urine and blood tests (including for HIV) Heart and eye tests Neurologic assessment and symptom checklist. Scans, bone marrow biopsy, and / or spinal tap Some participants will have lung tests. Participants will repeat these tests throughout the study and follow-up. Participants will have leukapheresis. Blood will be drawn from a plastic tube (IV) or needle in one arm then go through a machine that removes lymphocytes. The remaining blood will be returned to the participant s other arm. Participants will stay in the hospital about 2 weeks. There they will get: Two chemotherapy drugs by IV Their changed cells by IV Standard drugs for side effects Participants will have frequent follow-up visits for 1 year, then 5 visits for the next 4 years. Then they will answer questions and have blood tests every year for 15 years. ...

Inclusion Criteria

  • - INCLUSION CRITERIA: - Diagnosis - Patient must have a B cell ALL (inclusive of CML with ALL transformation) or lymphoma and must have relapsed or refractory disease after at least one standard chemotherapy regimen and one salvage regimen. In view of the PI and the primary oncologist, there must be no available alternative curative therapies and subjects must be either ineligible for allogeneic stem cell transplant (SCT), have refused SCT, recurred after SCT, or have disease activity that prohibits SCT at the time of enrollment. Patients who have undergone autologous SCT will be eligible, and patients that have undergone allogeneic SCT will be eligible if, in addition to meeting other eligibility criteria, they have no evidence of GVHD and have been without immunosuppressive agents for at least 30 days. Patients with Philadelphia chromosome + ALL must have failed prior tyrosine kinase inhibitor. - Patients must have measurable or evaluable disease at the time of enrollment, which may include any evidence of disease including minimal residual disease detected by flow cytometry. - CD22/CD19 Expression --CD19 expression must be detected on greater than 15% of the malignant cells by immunohistochemistry or greater than 90% by flow cytometry. The choice of whether to use flow cytometry or immunohistochemistry will be determined by what is the most easily available tissue sample in each patient. In general, immunohistochemistry will be used for lymph node biopsies, flow cytometry will be used for peripheral blood and bone marrow samples. CD22+ B cell malignancy is required and CD22 expression levels will be documented when available, but a specific level of expression is not an eligibility requirement; it may be documented as positive or negative. - Age: --Greater than or equal to 3 years of age (and at least 15 kg) and less than or equal to 35 years of age at time of enrollment (greater than or equal to 3 years to less than or equal to 30 years). NOTE: The first patient in each dose cohort must be greater than or equal to 18 years of age. - Clinical Performance --Clinical performance status: Patients greater than or equal to 16 years of age: Karnofsky greater than or equal to 50%; Patients < 16 years of age: Lansky scale greater than or equal to 50%. Subjects who are unable to walk because of paralysis, but who are upright in a wheelchair will be considered ambulatory for the purpose of calculating the performance score. - Patients must have normal organ and marrow function as defined below: - leukocytes greater than or equal to 750/mcL* - platelets greater than or euqual to 50,000/mcL* - total bilirubin less than or equal to 2 X ULN (except in the case of subjects with documented Gilbert s disease > 3x ULN) - AST(SGOT)/ALT(SGPT) less than or equal to 10 X institutional upper limit of normal - creatinine less than or equal to the maximum for age listed in the table below OR - creatinine clearance greater than or equal to 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal. - Age: less than or equal to 5. Maximun Serum Creatinine (mg/dL): less than or equal to 0.8 - Age: 6 to less than or equal to 10. Maximum Serum Creatinine (mg/dL): less than or equal to 1.0 - Age: >10. Maximum Serum Creatinine (mg/dL): less than or equal to 1.2 * if these cytopenias are not judged by the investigator to be due to underlying disease (i.e. potentially reversible with anti-neoplastic therapy); A subject will not be excluded because of pancytopenia greater than or equal to Grade 3 if it is due to disease, based on the results of bone marrow studies. -CNS Status: - a. Subjects with leukemia with the following CNS status are eligible only in the absence of neurologic symptoms suggestive of CNS leukemia, such as cranial nerve palsy: - CNS 1, defined as absence of blasts in cerebral spinal fluid (CSF) on cytospin preparation, regardless of the number of WBCs; - CNS 2, defined as presence of < 5/uL WBCs in CSF and cytospin positive for blasts, or > 5/uL WBCs but negative by Steinherz/Bleyer algorithm: - CNS 2a: < 10/uL RBCs; < 5/uL WBCs and cytospin positive for blasts; - CNS 2b: greater than or equal to 10/uL RBCs; less than or equal to 5/uL WBCs and cytospin positive for blasts; - CNS 2c: greater than or equal to 10/uL RBCs; greater than or equal to 5/uL WBCs and cytospin positive for blasts but negative by Steinherz/Bleyer algorithm. - b. Subjects with lymphoma ---Subjects must have no signs or symptoms of CNS disease or detectable evidence of CNS disease on MRI at the time of screening. Subjects who have been previously treated for CNS disease but have no evidence of disease at screening are eligible. -Contraception: - Patients of child-bearing or child-fathering potential must be willing to practice birth control from the time of enrollment on this study and for four months after receiving the preparative regimen. - Cardiac function: Left ventricular ejection fraction greater than or equal to 45% or fractional shortening greater than or equal to 28%, and no clinically significant ECG findings - Pulmonary Function - Baseline oxygen saturation >92% on room air at rest - Patients with respiratory symptoms must have a DLCO/adjusted > 45%. For children who are unable to cooperate for PFTs they must not have dyspnea at rest or known requirement for supplemental oxygen. - Ability of subject or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document. For subjects <18 years old their legal guardian must give informed consent. Pediatric subjects will be included in age appropriate discussion and verbal assent will be obtained for those > 7 years of age, when appropriate. EXCLUSION CRITERIA: Subjects meeting any of the following criteria are not eligible for participation in the study: - Recurrent or refractory ALL limited to isolated testicular or isolated central nervous system (CNS) disease. - Subjects with radiologically-detected CNS lymphoma or CNS 3 disease (presence of greater than or equal to 5/micro L WBCs in CSF and cytospin positive for blasts [in the absence of a traumatic lumbar puncture] and/or clinical signs of CNS leukemia and/or radiographic signs of leptomeningeal disease); - Hyperleukocytosis (greater than or equal to 50,000 blasts/micro L) or rapidly progressive disease that in the estimation of the investigator and sponsor would compromise ability to complete study therapy; - Pregnant women are excluded from this study because the study agents have the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with the study agents, breastfeeding should be discontinued. - Subjects will be excluded related to the following prior therapy criteria: - Systemic chemotherapy, anti-neoplastic investigational agents, or antibody based therapies =<2 weeks (6 weeks for clofarabine or nitrosoureas) prior to apheresis with the following exception: ---No time restricution with prior intrathecal chemotherapy, steroid therapy, hydroxyurea or ALL maintenance type chemotherapy (vincristine, 6-mercaptopurine, oral methotrexate, or a tyrosine kinase inhibitor for patients with Ph+ ALL) provided there is recovery from any acute toxic effects. - Radiation therapy =<3 weeks prior to apheresis with the following exception: ---No time restriction with radiation therapy if the volume of bone marrow treated is less than 10% and the subject has measureable/evaluable disease outside the radiation window. - History of allogeneic stem cell transplantation prior to apheresis that meet the following criteria: - Less than 100 days post-transplant - Evidence of active graft-verus-host disease (GVHD) - Taking immunosuppressive agents within 30 days prior to apheresis - Less than 6 weeks post donor lymphocyte infusion (DLI) - History of prior CAR therapy or other adoptive cell therapies prior to apheresis that meet the following criteria: - Less than 30 days post-infusion - Circulating CAR T cells (or genetically modified cells) >5% by flow cytometry in peripheral blood. - HIV/HBV/HCV Infection: - a. Seropositive for HIV antibody. (Patients with HIV are at increased risk of lethal infections when treated with marrow-suppressive therapy. Appropriate studies will be undertaken in patients receiving combination antiretroviral therapy in the future should study results indicate effectiveness.) - b. Seropositive for hepatitis C or positive for Hepatitis B surface antigen (HbsAG). - Uncontrolled, symptomatic, intercurrent illness including but not limited to infection, congestive heart failure, unstable angina pectoris, cardiac arrhythmia, psychiatric illness, or social situations that would limit compliance with study requirements or in the opinion of the PI would pose an unacceptable risk to the subject; - Second malignancy other than in situ carcinoma of the cervix, unless the tumor was treated with curative intent at least two years previously and subject is in remission; - History of severe, immediate hypersensitivity reaction attributed to compounds of similar chemical or biologic composition to any agents used in study or in the manufacturing of the cells.

Maryland

Bethesda
National Institutes of Health Clinical Center
Status: ACTIVE
Contact: National Cancer Institute Referral Office
Phone: 888-624-1937

Background:

- Acute lymphoblastic leukemia (ALL) accounts for approximately 25% of childhood cancer.

Survival rates have improved, but outcomes for some subgroups, including infants and

young adults remain poor, and survival for patients who relapse is < 50%, despite

allogeneic stem cell transplant following second remission.

- CD19 immune escape has been observed by several groups following CD19-CAR therapy for

B-ALL. Investigation of this phenomenon reveals a complex biology responsible for loss

or downregulation of CD19 expression observed in these cases.

- Sequential therapy using CD22-CARs to treat CD19 dim/lo escape is associated with rapid

development of resistance due to CD22 downregulation. This trial will test whether

simultaneous targeting of CD19 and CD22 using a novel bivalent CD19/22-CAR is safe and

feasible.

Objectives:

-Assess the safety of administering escalating doses of autologous CD19/CD22-CAR engineered T

cells that meet established release specifications in children and young adults with

CD19+CD22+ B cell ALL or lymphoma following a cyclophosphamide/fludarabine conditioning

regimen.

Eligibility:

-Patients between greater than or equal to 3 years and less than or equal to 35 years of age,

with CD19+/CD22+ B cell ALL or lymphoma who have relapsed or have refractory disease after at

least one standard chemotherapy regimen and one salvage regimen, with no alternative curative

options who meet standard Phase I eligibility criteria.

Design:

- Phase I, 3 + 3 dose escalation design using the following dose levels: -1: 1 x 10^5

transduced T cells/kg (+/- 20%); 1: 3 x 10^5 transduced T cells/kg (+/- 20%); 2: 1 x

10^6 transduced T cells/kg; and 3: 3 x 10^6 transduced T cells/kg (+/- 20%); 4: 1 x 10^7

transduced T cells/kg (+/- 20%).

- Patients will receive a lymphodepleting preparative regimen of fludarabine (25 mg/m^2/d

x 3 on Days -4, -3, -2) and cyclophosphamide (900 mg/m^2/d x 1 on Day -2) followed by

infusion of CD19/CD22-CAR T-cells on D0. Patients who are CAR pre-treated (with

exception for those with an interval HSCT) will receive increased lymphodepleting

preparative regimen of fludarabine (30 mg/m^2/d x 4 on Days -5, -4, -3, -2) and

cyclophosphamide (600 mg/m^2/d x 2 on Days -3, -2) followed by infusion of CD19/CD22-CAR

T-cells on D0.

- Patients will be evaluated sequentially for toxicity, antitumor effects, CAR expansion

and persistence, as well as research correlatives.

Trial Phase Phase I

Trial Type Treatment

Lead Organization
National Cancer Institute

Principal Investigator
Nirali N. Shah

  • Primary ID 180059
  • Secondary IDs NCI-2018-03654, 18-C-0059, NCI-2018-00358
  • Clinicaltrials.gov ID NCT03448393